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As West Nile virus (WNV) can cause lethal diseases in raptors, a vaccination prophylaxis of free-living and captive
populations is desirable. In the absence of vaccines approved for birds, equine vaccines have been used in falcons, but
full protection against WNV infection was not achieved. Therefore, two DNA vaccines encoding the ectodomain of the
envelope protein of WNV lineages 1 and 2, respectively, were evaluated in 28 large falcons. Four different vaccination
protocols were used, including electroporation and booster-injections of recombinant WNV domain III protein, before
challenge with the live WNV lineage 1 strain NY99. Drug safety, plasmid shedding and antibody production were
monitored during the vaccination period. Serological, virological, histological, immunohistochemical and molecular
biological investigations were performed during the challenge trials. Antibody response following vaccination was low
overall and lasted for a maximum of three weeks. Plasmid shedding was not detected at any time. Viremia, mortality
and levels, but not duration, of oral virus shedding were reduced in all of the groups during the challenge trial
compared to the non-vaccinated control group. Likewise, clinical scoring, levels of cloacal virus shedding and viral load
in organs were significantly reduced in three vaccination groups. Histopathological findings associated with WNV
infections (meningo-encephalitis, myocarditis, and arteritis) were present in all groups, but immunohistochemical
detection of the viral antigen was reduced. In conclusion, the vaccines can be used safely in falcons to reduce mortality
and clinical signs and to lower the risk of virus transmission due to decreased levels of virus shedding and viremia, but
full protection was not achieved in all groups.Introduction
West Nile virus (WNV) is a arthropod-borne Flavivirus
belonging to the Flaviviridae family and the Japanese en-
cephalitis serogroup complex [1]. At least seven different
lineages of WNV have been demonstrated by phylogenetic
analysis [2,3], with lineages 1 and 2 being of high zoonotic
importance [4]. The virus is distributed worldwide, except
for Antarctica [1,5] and epidemics in birds caused by* Correspondence: dominik.fischer@vetmed.uni-giessen.de
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in Europe [6-8].
Following an enzootic life cycle, WNV is transmitted
between arthropods, especially some mosquito species,
and a wide range of vertebrates [9,10]. Birds are regarded
as important virus reservoirs [11], whereas humans and
mammals (especially horses) represent mainly dead-end
hosts, potentially suffering from febrile disease, encephal-
itis, meningitis, poliomyelitis, and death [4,12,13]. In the
latter, viremia may be low, but in reptilian and avian spe-
cies, viral titers have been demonstrated to be high enough
for re-infection of mosquitoes [14]. Therefore, migratory
birds play an important role in spreading WNV [15-17].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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lead to severe morbidity and mortality in different avian
species, especially in raptors, crows and domestic geese
[18-27], which seemed to be particularly vulnerable to
WNV. In raptors, natural WNV infections have been
described in hawks [20,21,28-30], eagles [24-26,31-33],
condors [34] and different falcon species, such as pere-
grine falcons (Falco peregrinus), gyrfalcons (F. rusticolus),
prairie falcons (F. mexicanus), merlins (F. columbarius)
and American kestrels (F. sparverius) [27,30]. Experimen-
tal WNV infection studies have been performed in single
raptor species [27,35-37], demonstrating that falcons can
act as amplifying hosts, developing viremia, virus shed-
ding, and subclinical to fatal diseases.
Although WNV constitutes an obvious threat to free-
ranging and captive birds of prey in public or private collec-
tions, zoos, falconries or commercial breeding centers, a
vaccine destined for birds is not available. However, inacti-
vated vaccines and subunit vaccines destined for horses, as
well as experimental DNA vaccines, have been used in
avian species and evaluated either by the development of
neutralizing antibodies [34,38,39] or by experimental WNV
challenge [40-51]. Inactivated WNV vaccines and recom-
binant canary pox vaccines showed limited efficacy in large
falcons, especially if administered only twice before an ex-
perimental WNV lineage 1 challenge infection [51]. Even-
tually, a triple application scheme of both vaccines (given at
three-weekly-intervals) reduced the clinical signs suffi-
ciently, decreased or even abolished WN-viral RNA shed-
ding and prevented residual viral organ loads three weeks
post-challenge. However, full protection against a clinical
WNV infection was not always achieved.
DNA WNV vaccines have been used with very promis-
ing results in crows [40,41], songbirds [45], and raptors
[34,46]. In American robins (Turdus migratorius), Ameri-
can crows (Corvus brachyrhynchos) and fish crows (Cor-
vus ossifragus), viremia levels were effectively reduced by
the intramuscular administration of DNA vaccines. Add-
itionally, in crows, higher survival rates in WNV challenge
trials were achieved by vaccination compared to controls.
California condors (Gymnogyps californianus) showed
neutralizing antibody titers sixty days after vaccination,
which have been considered as effective protection
against naturally circulating WNV during the 2004
transmission season [34]. In red-tailed hawks (Buteo
jamaicensis), the stimulation of antibody development
following twofold vaccination was very low (only 21.4%
of the vaccinated birds had low titers), but a significant
reduction in mean viremia levels was achieved after
challenge [46]. However, differences in seroconversion
rate and virus shedding were not significant and the ab-
sence of morbidity and mortality in the control group dur-
ing WNV challenge trial limits its validity for clinical
protection.In light of the observed drawbacks of other vaccin-
ation strategies in large falcons, we tested a DNA vac-
cine candidate in combination with different application
schemes and confirmed its efficacy by live virus chal-
lenge. The vaccine encodes the envelope (E) protein of
WNV, the major target for neutralizing antibodies [52].
Our results indicate that protective immune responses
are induced upon DNA vaccination. However, the level
of protection is strongly dependent on the delivery sys-
tem, with in-vivo electroporation (EP) being the most
successful.Materials and methods
Animals and viruses
In total, 28 captive-bred, mature (>6 month old) falcons
(Falco rusticolus [n = 6]; F. cherrug [n = 1]; F. peregrinus
[n = 3]; F. cherrug x F. rusticolus [n = 14]; F. peregrinus
x F. rusticolus [n = 6]) originating from one collection
were used for this study. All birds were healthy in clinical
and endoscopic examination and were dewormed twice
(3 week interval) prior to the trial (25 mg/kg fenbendazol
orally, Panacur Suspension 2.5% ad us. vet., MSD Animal
Health GmbH, Unterschleißheim, Germany and 25 mg/kg
toltrazuril orally, Baycox 5% orale Suspension ad us. vet.,
Bayer Animal Health GmbH, Leverkusen, Germany).
ELISA (ID Screen© WN competition ELISA, IDVet, Gra-
bels, France) and the micro-virus neutralization test (VNT)
confirmed the absence of pre-existing WNV specific anti-
bodies. Additionally, the absence of Usutu virus specific
antibodies was confirmed by VNT using the USUV strain
Vienna_2001 (GenBank accession no. AY453411.1).
WNV lineage 1 NY99 (GenBank accession no. AF196835)
was propagated and titrated on Vero E6 cells and used for
virus challenge according to previous studies [37,51]. Virus
identity was verified by sequencing the WNV E protein
gene. Challenge virus doses contained 106 Tissue Culture
Infection Dose 50 (TCID50) diluted in 1 mL minimal essen-
tial medium (MEM) and were injected subcutaneously in
the inguinal region.Construction of WNV DNA vaccine candidates
Two DNA vaccines containing a modified version of
the pVax1 vector (Invitrogen, Karlsruhe, Germany) as
the backbone were prepared according to Schneeweiss
et al. [52].
The first vaccine (WNV-DNA-1) encoded the E pro-
tein ectodomain of WNV lineage 1 strains WNV 2000-
crow3356 (GenBank accession no. AF404756.1), which
is a close relative to the challenge WNV NY99 strain.
The second vaccine (WNV-DNA-2) encoded the E
protein ectodomain of WNV lineage 2 with the sequence
of the E protein of WNV strain goshawk Austria 361/10
(2009) (GenBank accession no. HM015884). DNA for
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dium chloride.
All DNA‐preparations used for vaccination in this study
were checked for their ability to express the E‐protein via
transient transfection assays in cultured cells, as described
in Schneeweiss et al. [52] before being injected into animals
(data not shown).
Expression and purification of recombinant WNV proteins
The recombinant domain III of WNV 2000-crow3356
was generated as a fusion protein with the maltose
binding protein (MBP), as described by Schneeweiss
et al. [52]. The MBP tag was enzymatically removed
from domain III by factor X cleavage according to the
manufacturers’ instructions (New England Biolabs,
USA). Here, 250 μg of protein in 150 μL phosphate
buffered saline (PBS) was mixed with 350 μL adjuvant
Montanide ISA 70 VG (Seppic, France) (= 500 μL in
total) and used for vaccination.
Falcon immunizations and WNV challenge studies
During the time of vaccination, falcons were housed in
outdoor hexagonal aviaries with a ground area of 125 m2
and height of 6 m in a commercial breeding center. The
area of the center was inspected and approved by the ani-
mal welfare (permission no.: 392016/2009) and species
conservation authorities (permission no.: AZ 68.337-02/
4.2) and approved as an area for genetic engineering
(BS003115275-1 dt Az. 40611/5801/501) according to the
German Genetic Engineering Act (Gentechnikgesetz,
GenTG). Vaccination studies were approved (reference
no. 7221.3-1.1.-056/10) on the basis of the EU council dir-
ective 86/609/EEC for the protection of animals used for
experiments. Vaccines were administered under isoflurane
inhalation anesthesia [53].
Each of the four vaccination groups (A-D) consisted of
five randomly selected falcons plus two randomly selected,
unvaccinated control falcons (which were merged into a
control group E (n = 8) eventually).
Falcons in groups A and B were vaccinated by intramus-
cular injection (pectoral muscle) with a plasmid (700 μg
per dose) encoding the E protein of the WNV lineage 1
(group A) or 2 (group B) and immune responses were
boosted once after three weeks post-vaccination (wpv).
Falcons in groups C and D received a plasmid (75 μg per
dose) encoding WNV E protein lineage 1 by intramuscu-
lar injection into the lower leg muscles immediately
followed by an in-vivo electroporation (EP) using the
electric pulse generator Clinivet (IGEA, Modena, Italy) ac-
cording to Schneeweiss et al. [52]. For this purpose,
feathers were plucked, exposing an area of 3 cm2 around
the injection site, and the four-electrode array was placed
on the skin to apply the electric pulses (Figure 1). While
group C animals were boosted after three weeks in thesame way, falcons of group D received two subcutaneous
injections of recombinant WNV E protein domain III and
ISA 70 adjuvant after two and four weeks. Depending on
the assigned vaccination group, the control animals
(group E) received injections of sodium chloride, EP and/
or adjuvant, respectively, at the same time as the respect-
ive vaccinated birds. Each bird was kept under constant
observation for 3 h after each treatment. During the seven
weeks of the vaccination course, the health status of all fal-
cons was assessed daily and a clinical examination was per-
formed every seven days, including palpation of the vent,
auscultation of the lungs and heart, and inspection of nares,
pharynx, mucus membranes, feet, skin and muscles at the
vaccination sites. Blood samples and swabs from the oro-
pharynx and cloaca were taken weekly for WNV antibody
determination by ELISA, VNT [51] and DNA plasmid
detection by PCR, respectively.
After seven (groups A & B) or six weeks (groups C &
D), respectively, falcons were transferred to an animal trial
unit and challenged under biosafety level 3 conditions
with WNV strain 1 NY99. Challenged falcons were exam-
ined daily for general condition, posture, plumage, behav-
ior, excrements, neurological status, hydration status,
respiration and food uptake [51]. Measurements of body
temperature, weight, condition score and hydration status
were performed under isoflurane inhalation anesthesia,
and samples were taken (blood, pharyngeal and cloacal
swabs) on 0, 3, 6, 8, 10, 12, 14 and 19/20/21 days post-
infection (dpi) [51]. Clinical findings were documented
using a clinical scoring system: a score of 0 referred to a
healthy/inconspicuous status, 1 to a mildly affected status,
score 2 to a moderately affected status and 3 to a severely
affected status. Deceased animals were given a score of 4.
Birds were euthanized on 19/20/21 dpi or earlier, when
falcons showed seizures, torticollis, somnolence or apathy.
Post-mortem examinations were performed on all dead
birds, and included the sampling of organs (lung, heart,
spleen, kidney, liver, and brain) and subsequent storage of
samples in supplemented MEM at −70 °C and in formalin,
as described earlier [37,51].Antibody detection
Sera were assayed by ID Screen© WN competition ELISA
(IDVet) following the manufacturer’s instructions, with a
40% competition as a cut-off value. Additionally, VNT on
Vero cells were conducted using two-fold dilutions (in
MEM) and homologous challenge virus (100 TCID50)
following the protocol by Seidowski et al. [54]. Cytopatho-
genic effects were assessed after seven days using forma-
lin-fixation and crystal violet staining, and neutralizing
titers were calculated using the Behrens-Kaerber method,
as previously described [51]. Similarly, sera were checked
for neutralizing antibodies against USUV using the strain
Figure 1 Vaccination and application of in-vivo electroporation in falcons. The intramuscular injection of the vaccine and the application
of in-vivo electroporation using a four-electrode array and an electric pulse generator (Clinivet, IGEA, Modena, Italy) are shown on right
lower leg muscles of a falcon in group C. The feathers were plucked in a 3 cm2 area around the injection site.
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VNT.
Detection of plasmid shedding
During the vaccination period, pharyngeal and cloacal
swabs were examined for the presence of WNV plasmid
DNA originating from WNV-DNA-1 and WNV-DNA-2.
For this purpose, swabs were incubated in PBS and DNAs
were extracted using E.Z.N.A Plasmid Mini Kit I (Omega
bio-tek, Norcross, GA, USA). Afterwards, 10 μL eluate
was examined by PCR using Taq polymerase (NEB,
Ipswich, MA, USA) in a Biometra Thermocycler and




GGCCAGAGCTTGGTGCAAT-3′) with 394 and 379
base pairs, respectively. A detection level of 0.5 pg
plasmid was determined per PCR.
Virus isolation and viral genome detection
Virus isolation was performed according to Angenvoort
et al. [51] using serial dilutions of organ homogenate su-
pernatants and bovine serum albumin-1 (BA-1) dilutions
for the inoculation of Vero cells. After seven days, cells
were formalin-fixed and stained with crystal violet; virus
titers were calculated using the Spearman and Kaerber
method, as described recently [51]. Viral RNAs were
isolated from oral and cloacal swabs, from organ hom-
ogenate supernatants using the QIAamp® Viral RNA Kit
(Qiagen) and from blood in BA-1 using the RNeasy®
Mini Kit (Qiagen) according to the manufacturer’s in-
structions [51]. In parallel with these samples, an in-
ternal control RNA (IC RNA) containing 2 × 105 copies/
μL was extracted. Viral RNA and IC RNA were stored at
−70 °C for further analysis. Two qRT-PCRs, amplifying
the 5′NTR-region or the NS2A-region, respectively,
were used for WNV virus detection and quantificationas described before [55]. Cycle threshold (Ct) values
below 35 were regarded as positive, from 35 to 40 as
suspicious and above 40 as negative.
Histological and immunohistochemical examinations
Formalin-fixed tissue samples were embedded in paraf-
fin, cut into 3 μm sections, rehydrated and stained with
hematoxylin/eosin (H&E) or by using monoclonal anti-
bodies (mabs) to WNV in immunohistochemistry (IHC).
Mab 15R4 (kindly provided by P. Emmerich, Bernhard
Nocht Institut, Hamburg, Germany) and mab 3B2 (kindly
provided by Davide Lelli, Istituto Zooprofilattico Speri-
mentale della Lombardia e dell’Emilia Romagna, Brescia,
Italy), were diluted in goat serum (1:20 and 1:80, respect-
ively) and the slides were immunostained as described
before [51]. Briefly, endogenous peroxidase was blocked
using H2O2/methanol for 30 min. As a pretreatment, a
Proteinase K digestion for 15 min at 37 °C using a concen-
tration of 4 μg/mL (mab 15R4) and heating with citrate
buffer (pH 6.0) for 10 min (mab 3B2) were applied,
respectively. The slides were finally developed using
Mouse Envision HRP (Dako Diagnostics, Dako Deutsch-
land GmbH, Hamburg, Germany) and diaminobenzidine.
Hearts, spleens, brains and the virus injection sites were
evaluated and scored for their percentage of positive tis-
sues/cells according to previous studies [51]. Thereby, an
organ score of 0 was negative (= no cells affected), 1
was mildly affected (<1% positive cells), 2 was moder-
ately affected (≥1% and <5% positive cells) and 3 was
severely affected (≥5% positive cells).
Statistical analysis
WNV antibodies were compared within and between
birds from vaccination and control groups using Fisher’s
exact test. The mean duration of illness and clinical scores
of all days for each falcon were compared using one-sided
Wilcoxon rank sum test with continuity correction. All
time points were calculated separately, except 19, 20 and
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For testing the duration of illness, a clinical score of 4 was
excluded from the analysis. Each group was compared to
the control group separately, whereby p-values below
α-levels of 0.05 were classified as significant.
Levels of oral and cloacal virus shedding and of viremia
were analyzed using ANOVA including all sampling days.
The duration of virus shedding and viremia were evaluated
using one-sided Wilcoxon rank sum test with continuity
correction and a cut-off Ct value of 35.0. Likewise, this test
was used for the analysis of viral organ loads (in heart,
spleen, kidney, brain). All statistical tests were performed
using R software [56].
Results
The efficacy of two different WNV DNA vaccines in fal-
cons was determined by a) assessing their tolerance, safety
and potency to elicit specific antibody responses and b) by
challenging the vaccinated and control birds with a semi-
lethal WNV NY99 dose.
Vaccine tolerance and safety
Following vaccination and sampling, behavior, food uptake,
movement or general health of the falcons were not af-
fected at any time. The body weight of the vaccinated and
control animals varied only slightly between +3.5% and
−6.6%. In group B, two birds (F32, F33) developed an
edematous/gelatinous texture of pectoral muscle 1 wpv.Figure 2 Antibodies detected by ID Screen© WN competition ELISA d
detected by the ID Screen© WN competition ELISA (IDVet, Grabels, France)
converted to signal/noise% (S/N%) ratio (S/N% = ODsample/ODnegative co
being equivocal and >50% negative. The threshold for positive results is in
whiskers represent the minimum and maximum values, respectively. Outlie
includes 50% of the values for each group. Vaccination groups with a statistica
by ELISA and micro-virus neutralization test in comparison to group E are labelOne falcon in group D demonstrated 0.4 cm × 0.5 cm sized,
yellowish, dense skin texture at the vaccination site 1 and
2 weeks after boost vaccination (F56, 5-6 wpv) with recom-
binant WNV protein. The vaccination sites of all other
birds were macroscopically unsuspicious. In none of the
oral and fecal swabs from the falcons was WNV plasmid
DNA detected at any time.Vaccination induced antibody responses
Antibody responses are shown in Figures 2 and 3. All con-
trol birds (group E) remained negative by ELISA and
VNT. In group A, one bird (F25) was ELISA-positive from
5 wpv onwards. At the same time, two other falcons (F29,
F30) had low antibody titers of 1:10 by VNT, which lasted
for 3 weeks in one bird. All other individuals of this group
remained negative in both tests throughout the complete
trial.
In group B, one falcon (F31) was ELISA-positive 4 wpv
and another falcon (F33) had a low antibody titer of 1:20
5 wpv by VNT. Both individuals were negative at all other
time points examined and all of the other birds of this
group remained negative throughout the entire vaccin-
ation period.
Three falcons in group C (F49, F52, F53) were positive
by ELISA from 4 wpv onwards. One of these (F52) and
one other falcon (F50) had antibody titers of 1:15 and 1:10
by VNT, respectively, lasting for 1-2 weeks.uring the vaccination period in falcons. Antibodies of all groups
during the vaccination period are shown. Optical density at 450 nm is
ntrol * 100), with values ≤40% considered positive, >40% and ≤50%
dicated as a solid red line. In box-and-whisker plots, the ends of the
rs are represented as black dots instead of whisker-ends and the box
lly significant difference in development of antibody production detected
ed with an asterisk (Fisher’s exact test, p-values < α-levels of 0.05).
Figure 3 Antibodies detected by the micro-virus neutralization test (VNT) against homologous challenge WNV. Antibody titers of all
groups determined by VNT against the homologous challenge virus (neutralization titer) during the vaccination period are shown. In box-and-whisker plots,
the ends of the whiskers represent the minimum and maximum values, respectively. Outliers are represented as black dots instead of whisker-ends and
the box includes 50% of the values for each group. Vaccination groups with statistical significant difference in development of antibody production de-
tected by ELISA and micro-virus neutralization test in comparison to group E are labeled with an asterisk (Fisher’s exact test, p-values < α-levels of 0.05).
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and only two birds (F57, F58) had an antibody titer of 1:15
by VNT 6 wpv.
In groups A and C, but not in groups B and D, Fisher’s
exact test demonstrated a significantly increased presence
of WNV antibodies compared to group E.
Clinical signs following WNV NY99 challenge
Details on the clinical scores and development of body
weights are provided in Figure 4. In the control group E,
two of the eight control birds (F55, F27) had to be eutha-
nized 3 dpi and 14 dpi, respectively, due to severe central
nervous signs (clinical score 3) such as seizures, torticollis,
ataxia and an inability to stand. Two other birds (F42,
F51) were found dead on 5 dpi and 8 dpi, respectively,
after showing greenish discoloration of urates, enophthal-
mos, inappetence and ruffled feathers on the previous day.
Similar symptoms (clinical scores 2-3) were observed in
the four other control birds between 3 dpi and 11 dpi
temporarily, but clinical signs ceased afterwards. All con-
trol birds dropped their weight from 1.56% to 27.01% (me-
dian: 5.75%).
Four falcons of group A had clinical scores equal to
or above 2 and two falcons (F26, F29) died on 4 dpi
and 8 dpi, respectively. Body weight dropped slightly in
the three survivor birds (0.7-7.1%) and decreased rap-
idly and severely in the two deceased falcons (21.9%
and 10.5%, respectively). Median weight loss of all birds
in group A was 6.8%.
In group B, two falcons (F31, F33) had clinical scores
of 2 on one day and one falcon (F35) had clinical scoresof 2 and 3 over several days. No bird died and weight
losses ranged from 0.76% to 10.9% (median: 9.6%).
One falcon (F50) of group C had a clinical score of 2
on one day (7 dpi) and another bird (F54) had this score
after ten days. However, clinical score in the latter in-
creased to 3 for one day. No falcon died and the weight
loss in four birds ranged from 9.1% to 16% (median:
11.6%), whereas in one bird (F54), it was up to 27.1%.
In group D, one falcon (F60) had a clinical score of 2 and
one falcon (F59) had a clinical score of 3. The latter animal
was euthanized on 18 dpi because of ataxia, hypermetria
and weight loss of 30.9%. The other birds in this group
dropped weight from 1.5% to 12% (median: 8.7%).
In groups B, C and D, but not in group A, significantly
reduced clinical scores were demonstrated by Wilcoxon
rank sum test compared to the control group E (p-values
0.01154, 0.02391, 0.04592; for group A 0.1703).
Virus shedding, viremia and antibody response after
challenge infection
Oral and cloacal virus shedding data are shown in Figures 5
and 6, virus genome detection in the blood in Figure 7 and
virus re-isolation data from blood in Figure 8. Serology
results are depicted in Figures 9 and 10.
All birds of the challenge control group (group E) shed
WNV orally and in their feces from 3 dpi onwards, with
Ct values varying from 17.48 to 34.75. However, in the
four surviving control birds (F13, F24, F36, F43), viral
genomes were sometimes not detected (F36 at 20 dpi
and F13, F24, F43 after 8-14 dpi). Viral genomes were
detected in the blood of all falcons from 3 dpi onwards,
Figure 4 Clinical score: following criteria were classified daily: general condition, posture, plumage, behavior, excrements, neurological
status, hydration status, respiration and food uptake (alterations: +++ = 3 points, ++ = 2 points, + = 1 point, +/ - = 0.5 points and - = 0
points). Points were summed up and total points of one day were classified in a clinical score system: 0–0.5 points = 0 = healthy; 1–4.5 points = 1
=mild affection; 5–10.5 points = 2 =moderate affection; 11 points and more = 3 = severe affection; 4 = dead. Weight presents the change of body
weight (− = decrease, + = increase) in percent as comparison of the first and the last measurement of each falcon during the trial. Vaccination
groups with statistical significant difference in sum of clinical scores in comparison to group E are labelled with an asterisk (one-sided Wilcoxon
rank sum test with continuity correction, p-values < α-levels of 0.05). Abbreviation: dpi (days post infection).
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ceased in most of the survivors on 6-14 dpi (all except
F36), while it persisted in the fatally affected falcons
until death. Virus was successfully re-isolated and ti-
trated from blood taken on 3 and 6 dpi (yielding titers in
the range of 101.75-106.5 TCID 50/mL respectively). First,
WNV-specific neutralizing antibodies were detected on
3 dpi (F36, F55) or 6 dpi (F13, F24, F27, F43), respect-
ively, and ranged from 1:10 to 1:80. However, two of the
eight falcons which did not survive the WNV challenge
did not develop a neutralizing antibody response (F42,
F51). In the survivors (F13, F24, F36, F43), the antibody
titers increased to a maximum of 1:1280 at the end of
the observation period.
In oral and cloacal swabs and in blood taken from birds
of group A, viral genomes were only detectable between 3
dpi and 8 dpi. A solitary positive result in one bird (F28,Ct value of 32.82 at 14 dpi), which was negative by qRT-
PCR at all other time points, may be due to an artifact.
Virus re-isolations from blood were successful in all birds
on 3 dpi (101.75-105 TCID 50/mL) and in two birds (F25,
F26) also from samples taken at 6 dpi (102.5 and 103.5
TCID50/mL). Antibody titers from 1:15 to 1:320 were
detectable in one bird (F30) from 3 dpi and in three
birds from 6 dpi onwards, increasing to a maximum of
1:5120 during the trial. However, in the two birds from
this group which eventually died, antibody titers
remained low (1:40) after challenge (F26) or disap-
peared (F29) after being low (1:10) before challenge.
In group B, animal viral genomes were detected in
pharyngeal swabs up to 10 dpi and in cloacal swabs of two
birds (F34, F35) even until 19-21 dpi. Birds were viremic on
3 and 6 dpi, but not at later time points. Virus titers in
blood on 3 dpi were 101.75-103 TCID50/mL. Initial antibody
Figure 5 Oral virus shedding of falcons during WNV lineage 1 challenge. The oral virus shedding of falcons during challenge is displayed.
Cycle threshold values (Ct values) of swabs for all groups are shown. In box-and-whisker plots the ends of the whiskers represent the minimum
and maximum values, respectively. Outliers are represented as black dots instead of whisker-ends. This includes 50% of the values of each group,
with the median value of each group being represented by a line in the middle. Vaccination groups with statistical significant difference in the
level of oral viral genome shedding in comparison to group E are labeled with an asterisk (ANOVA over all sampling days, p-values < α-levels of
0.05). There was no group with a statistically significant difference in duration of oral viral genome shedding (one-sided Wilcoxon rank sum test
with continuity correction, cut-off Ct value 35.0, p-values < α-levels of 0.05).
Figure 6 Cloacal virus shedding of falcons during WNV lineage 1 challenge. The cloacal virus shedding of falcons during challenge is
displayed. Cycle threshold values (Ct values) of swabs for all groups are shown. In box-and-whisker plots the ends of the whiskers represent the
minimum and maximum values, respectively. Outliers are represented as black dots instead of whisker-ends. The box includes 50% of the values of
each group and median value of each group is represented by a line in the middle. Vaccination groups with a statistically significant difference in the
level of cloacal viral genome shedding in comparison to group E are labeled with an asterisk (ANOVA over all sampling days, p-values < α-levels of
0.05). There was no group with a statistically significant difference in duration of cloacal viral genome shedding (one-sided Wilcoxon rank sum test with
continuity correction, cut-off Ct value 35.0, p-values < α-levels of 0.05).
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Figure 7 Viremia of falcons during WNV lineage 1 challenge detected by qRT-PCR. The cycle threshold values (Ct values) of whole blood for all
groups during the challenge period are displayed. In box-and-whisker plots the ends of the whiskers represent the minimum and maximum values,
respectively. Outliers are represented as black dots instead of whisker-ends. The box includes 50% of the values of each group and median viremia
value of each group is represented by a line in the middle. Vaccination groups with a statistically significant difference in the level of viremia in
comparison to group E are labeled with an asterisk (ANOVA over all sampling days, p-values < α-levels of 0.05). There was no group with a statistically
significant difference in duration of viremia (one-sided Wilcoxon rank sum test with continuity correction, cut-off Ct value 35.0, p-values < α-levels
of 0.05).
Figure 8 Viremia of falcons during WNV lineage 1 challenge detected by virus titration. The results of blood titration for all groups during the
challenge period are given in log10 tissue culture infection dose 50 per mL (TCID50/mL) whole blood. In box-and-whisker plots the ends of the whiskers
represent the minimum and maximum values, respectively. Outliers are represented as black dots instead of whisker-ends. The box includes 50% of the
values of each group and the median viremia value of each group is represented by a line in the middle.
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Figure 9 Antibodies detected by ELISA during challenge in falcons. Antibodies of all groups detected by the ID Screen© WN competition ELISA
(IDVet, Grabels, France) during the challenge period are shown. Optical density at 450 nm is converted to signal/noise% (S/N%) ratio (S/N%=ODsample/
ODnegative control * 100), with values≤ 40% considered positive, >40% and ≤50% equivocal and >50% negative. The threshold for positive results is
indicated as a solid red line. In box-and-whisker plots, the ends of the whiskers represent the minimum and maximum values, respectively. Outliers are
represented as black dots instead of whisker-ends and the box includes 50% of the values for each group.
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maximum titers of 1:2560 at the end of the study.
In group C, viral genomes were detected in oral and
pharyngeal swabs and in blood up to 14 dpi. One bird
(F54) shed virus orally until 21 dpi. Blood Ct values wereFigure 10 Antibodies detected by micro-virus neutralization test (VNT
determined by VNT against homologous challenge virus (neutralization
plots the ends of the whiskers represent the minimum and maximum va
whisker-ends. The box includes 50% of the values of each group and mein the range of 21.40 to 34.5. Virus re-isolations were suc-
cessful from blood samples taken from three birds on 3
dpi (titers 101.75-102.75 TCID50/mL), but not from blood
samples taken at later time points. Antibody titers were
detected in two falcons (F52 and F53) already by 3 dpi and) during challenge in falcons. Antibody titers of all groups
titer) during the challenge period are shown. In box-and-whisker
lues, respectively. Outliers are represented as black dots instead of
dian value of each group is represented by a line in the middle.
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already antibodies on 0 dpi as a result of the vaccination.
Initially ranging from 1:10 to 1:480, antibody titers in-
creased to maximum titers 1:7680 and lasted until to the
end of the study.
In group D, viral genomes were detected in pharyngeal
swabs beginning at 3 dpi until the end of the observation
period and until 14 dpi in cloacal swabs and blood. Virus
re-isolations were successful in two birds (F60, F59) on 3
dpi with 101.83 TCID50/mL and 102.75 TCID50/mL, re-
spectively, and additionally in one of these birds on 6
dpi (102 TCID50/mL). Antibody titers in four birds
ranged from 1:10 to 1:20 on 3 dpi; however, antibodies
were present on 0 dpi in two of these birds (F57, F58).
The titers increased in all birds, up to maximum levels
of 1:3840. One bird (F59) with a low neutralizing anti-
body titer on 6 dpi (1:20), but without a strong humoral
response (maximum titers of 1:320), showed neuro-
logical signs and apathy and was eventually euthanized
on 18 dpi.
ANOVA demonstrated that oral (p values groups A-D:
0.0006594, 0.000002827, 0.00006856, 0.000122) and
cloacal (p values groups A, B, D: 0.0005033, 0.0002035,
0.03737; for group C 0.06771) virus shedding and virus
detection in blood (p values groups A-D: 0.001057,
0.000000268, 0.0006269, 0.0005634) were significantly
reduced in all groups compared to the control group.
However, the duration of oral shedding (p values groups
A-D: 0.1013, 0.2041, 0.4702, 0.3014) and viremia (p values
groups A-D: 0.1566, 0.09665, 0.4108, 0.4108) was not
significantly different, as determined by the Wilcoxon
rank sum test.
Post mortem examination, histopathology and
immunohistochemistry
A summary of the pathological and immunohistochemi-
cal findings is provided in Table 1.
The gross-pathology, histopathology and IHC of the
non-vaccinated positive controls (group E) were previ-
ously described [51]. Briefly, the most consistent finding
associated with WNV infection was a non-suppurative
(meningo)-encephalitis (4/8) and an acute or subacute,
lymphohistiocytic, necrotizing myocarditis (5/8). A mod-
erate, non-suppurative, necrotizing arteritis was seen in
the spleen of one bird only (F24). Virus antigens were
detected by IHC in brains, hearts and spleens and at
injection sites of the fatally diseased animals (4/8),
whereas challenge survivors displayed only scant (2/8)
or no (2/8) WNV antigen staining.
One falcon (F29) of group A died 4 dpi and showed a
severe, acute, hemorrhagic enteritis with positive anti-
gen staining at the injection site, but without other
signs typically associated with WNV infections. In all
other birds (4/5) a widely distributed, moderate, acute,non-suppurative (meningo)-encephalitis was diagnosed.
Additional findings included an acute to subacute, mild,
necrotizing myocarditis (2/5), an acute, mild, necrotiz-
ing arteritis in the kidney (2/5), a necrosis of the splenic
periarteriolar lymphoid sheaths (PALS) of different
degrees with fibrin deposition (4/5), a mild lymphoplas-
macellular interstitial nephritis (1/5) and a mild lym-
phohistiocytic neuritis with axonal degeneration (2/5).
The vaccination sites were not altered in any bird of this
group. By IHC, scattered antigen was detected at the
virus injection sites in three birds (3/5) and in the brains
of two birds (2/5) (Figure 11), with one of these (F 26)
having antigen in all regions of the brain and addition-
ally in the heart.
One falcon in group B (F35) demonstrated only a slight
lymphohistiocytic pancreatitis. All other animals (4/5)
demonstrated a mild to moderate, widely distributed,
acute, non-suppurative meningoencephalitis. Additionally,
a mild, acute, necrotizing myocarditis (2/5), a mild, necro-
tizing arteritis in the gut connective tissue (1/5), a mild lym-
phohistiocytic hepatitis (1/5) and neuritis (1/5) were seen.
The vaccination site of one animal (1/5) displayed a mild
lymphohistiocytic myositis. No WNV antigen was detected
by IHC in any bird of this group.
Four birds (4/5) of group C had acute, non-suppurative
encephalitis of different degrees, varying from slight le-
sions (1/4) in the cerebellum/cerebrum to moderate and
severe inflammation of all brain areas (1/4) and the men-
inges (2/4). Additional findings included an acute necro-
tizing myocarditis (2/5), a mild to moderate, acute,
necrotizing arteritis (2/5), a mild lymphohistiocytic neur-
itis (3/5) and nephritis (1/5). At the vaccination sites, fol-
licular aggregated infiltrations of mononuclear cells with
mild lymphocytolysis (2/5) and an acute lymphohistiocytic
myositis (1/5) were seen. IHC revealed a mild staining re-
action in the spleen or brain and heart, respectively, of
two falcons (2/5) (Figure 12), whereas all other birds
remained negative.
An acute, non-suppurative meningoencephalitis of
varying degrees was observed in all birds from group D
(5/5). Additional findings included an acute to subacute,
mild to moderate, necrotizing myocarditis (3/5), a mild,
acute, necrotizing arteritis (1/5), and a mild, acute to
subacute, non-suppurative neuritis (4/5) and nephritis
(1/5). The vaccination sites had infiltrations of follicular
aggregated mononuclear cells in the connective tissues
(1/5) and a granulomatous dermatitis (2/5). In IHC, one
bird (F59, Figures 11 and 13) was severely affected in
cerebrum (15% positive tissue) and mildly affected in
cerebellum and diencephalon. However, IHC results in
the spleen and brain of two falcons (F58, F60) were
inconclusive.
In general, the occurrence of scattered antigen in neu-
rons, glial cells and cell processes of the brain, in
Table 1 Histopathological (HE) and immunohistochemical (IHC) results from vaccinated falcons and non-vaccinated
controls infected with WNV lineage 1 NY’99
Grp ID Dpi Brain Heart Spleen Inject. Vacc. Others
HE IHC HE IHC IHC IHC Qual Deg Art PALS Neu Nep Hep Ent Pan Ser Sep
A F25 20 2 0 1 0 0 1 - 0 1 0 0 0 0 1 c 0 0 0
F26 8* 2 1 0 1 0 1 - 0 0 3 0 0 0 0 0 0 0
F28 21 2 0 1 0 0 0 - 0 0 1 1 1 0 0 0 0 0
F29 4* 0 0 0 0 0 1 - 0 0 2 0 0 0 3 h 0 0 0
F30 19 2 1 0 0 0 0 - 0 1 1 1 0 0 0 0 0 0
B F31 21 2 0 0 0 0 0 Nsp. 1 1 0 0 0 1 0 0 0 0
F32 19 2 0 1 0 0 0 - 0 0 0 0 0 0 0 0 1 0
F33 21 1 0 1 0 0 0 - 0 0 0 0 0 0 1 c 0 0 0
F34 20 1.5 0 0 0 0 0 - 0 0 0 1 0 0 0 0 0 0
F35 19 0 0 0 0 0 0 - 0 0 0 0 0 0 0 1 0 0
C F49 20 2.5 0 0 0 0 0 Nsp. 0.5 1 0 1 0 0 0 0 0 0
F50 20 3 0 0.5 0 0 0 - 0 0 0 1 0 0 0 0 0 0
F52 19 0.5 0 0 0 0 0 Fol. 0 0 0 0 0 1 c 0 0 0
F53 19 0 0 0 0 1 0 Fol. 2 0 0 0 0 0 0 0 0
F54 21 2 1 1 1 0 0 - 0 0 0 1 1 0 0 0 0 0
D F56 19 1 0 0 0 0 0 - 0 0 0 1 0 1 1 c 0 0 0
F57 21 2.5 0 0 0 0 0 Fol. 0 0 0 0 0 0 0 0 0
F58 21 2 0 10 0 0 0 Gran. 3 0 0 1 1 0 0 0 0 0
F59 18* 2 3 1.5 0 0 0 Nsp. 1 0 0 1 0 0 0 0 0 0
F60 20 1.5 0 1.5 0 0 0 Gran. 2 1 0 1 0 0 0 0 0 0
E F13 19 2 0 0.5 0 0 0 ND 0 0 1 0 0 0 0 0 0
F24 20 2 1 2 0 0 0 ND 2 0 1 0 1 0 1.5 1 0
F27 14* 1.5 1 3 0 0 1 ND 0 0 1 1.5 0 1 0 0 0
F36 20 1.5 0 1 0 0 0 ND 0 0 1 0 0 0 0 0 0
F42 5* 1 0 0 0 p 1 2 ND 0 3 1 0 0 0 0 0 0
F43 20 1.5 0 2 1 1 1 ND 0 0 1 0 0 1 1.5 0 0
F51 8* 0.5 0 0 1 3 2 ND 0 3 0 1.5 u 1 0 0 0 0
F55 3* 0 0 0 1 0 3 ND 0 3 0 0 0 0 0 0 2
Unspecific findings seen in most of the 28 challenged animals included a pale (26/28) and enlarged spleen (24/28) with severe lymphoid depletion (20/28) and a
marked lymphcytolysis in the remaining follicles (20/28), bloated foamy macrophages in spleen (23/28) and in liver (27/28) which shows also an extramedullary
hematopoiesis (24/28).
Abbreviations: Grp (group); ID (identification number); Dpi (days post infection); * (died/euthanized before end of the trial); Inject. (virus injection site); Vacc.
(vaccination site); HE (hematoxylin and eosin stain); IHC (immunohistochemistry); Qual (quality); Deg (degree); Art (arteriitis); PALS (periarteriolar lymphoid sheat);
Neu (neuritis); Nep (nephritis); Hep (hepatitis); Ent (enteritis); Pan (pancreatitis); Ser (serositis); Sep (septicemia); Nsp. (non-suppurative inflammation); Fol. (follicular
aggregated mononuclear cells); Gran. (granulomatous inflammation); p (petechia); u (uratnephritis); c (detection of coccidial parasites); h (hemorrhagic).
The numbers for HE examination indicate a weak (0.5), mild (1), mild to moderate (1.5), moderate (2), moderate to severe (2.5) and severe (3) alteration. The score
for IHC indicate no positive cells (0), ≤1% positive (1), >1% and ≤5% positive (2) and >5% positive tissue structures (3).
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injection site of vaccinated falcons were similar to findings
in the control birds.
Virus loads in organs
The results of qRT-PCR and virology from selected organ
samples are summarized in Table 2. In the organs of all fal-
cons of group E viral genomes were detected with lowest
Ct values of 16.7 (equivalent to 402 895 copies/mg). Allorgans of the four fatally affected birds (F27, F42, F51, F55)
were qRT-PCR positive, as were 2-5 organs of the four
challenge survivors (F13, F24, F36, F43). Accordingly, virus
re-isolations were possible from organs of the four de-
ceased birds in most cases (101.75-104.75 TCID50/100 μL).
In the four survivors virus isolations were successful only
from the brain samples of two birds (F13, F43).
In all birds of group A, viral genomes were detected in
the brain and also in the kidneys in four birds. Heart,
Figure 11 Immunohistochemistry of the cerebrum of vaccinated falcons. Single cell necrosis and mild glial reaction with distinct
amounts of viral antigen within neurons and glial cells are demonstrated in the cerebra of two falcons. (A) Falcon in group D, 18 dpi, mab
15R4, bar 50 μm. (B) Falcon in group A,19 dpi, mab 15R4, bar 20 μm.
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vors, but positive in two falcons (F26, F29) which died
during the study. In the latter two falcons, viruses could
be isolated from all organs (except from heart in F29),
but only from brain (100.75-105.75 KID50/100 μL) in two
other falcons (F25, F30) and from none of the organs in
one falcon (F28).
Brains of three falcons (F31, F32, F34) belonging to
group B carried viral genomes and the kidney of one
falcon (F32) was also qRT-PCR-positive. None of the
other birds and none of the organs were positive by
qRT-PCR and virus re-isolation failed in all birds.
In group C, qRT-PCR was positive in three birds (F49,
F50, F54) in the brain, but not in other organs. ViralFigure 12 Immunohistochemistry of the spleen of a vaccinated
falcon. The spleen of a falcon in group C, 19 dpi is displayed.
Antigen was detected in single mononuclear cells in follicles, mab
15R4, bar 50 μm.genomes were not detected in any other bird and the
virology was negative in all birds for all organs.
Viral genomes were detected in the brain in all birds
in group D, in one falcon (F57) additionally in the kid-
neys and in another falcon (F59) additionally in all other
organs. In the latter falcon, which had to be euthanized
during the trial, virus re-isolation was successful from
the brain with a result of 102.75 TCID50/100 μL, whereas
it failed in all other birds of this group in all organs.
Wilcoxon rank sum test revealed that the viral genome
detections was significantly reduced in all organs of group
B animals (p values of brain, spleen, kidney and heart:
0.01767, 0.02228, 0.009749, 0.008443), in the spleen, kidney
and heart of group C animals (p values 0.03582, 0.005709,Figure 13 Immunohistochemistry of the telencephalon of a
vaccinated falcon. The telencephalon of a falcon in group D, 18
dpi, is displayed. Regions close to ventricles, most notably the area
parahippocampalis, were severely affected, mab 15R4, bar 100 μm.
Table 2 Viral load of organs in Ct values, copies per mg organ and tissue culture infectious dose 50 (TCID50) per mg organ
Falcons Brain Spleen Kidney Lung Liver Heart
Grp ID Dpi Ct Copies TCID Ct Copies TCID Ct Copies TCID Ct Copies TCID Ct Copies TCID Ct Copies TCID
A F25 20 30.5 40.6 0.5 N 0 0 N 0 0 N 0 0 N 0 0 N 0 0
F26 8 17.4 360248.4 48899.3 18.4 287861 432 22.1 28394.8 558.7 29.1 384.8 1814 19.8 43699.3 312.8 21.1 43844.8 139.7
F28 21 31.1 84.6 0 N 0 0 31 155.6 0 N 0 0 N 0 0 N 0 0
F29 4 32.9 12.2 0.6 25.2 3941.3 26.8 26.5 1081.2 1.9 28.3 511.6 5.3 27.9 448.2 0.7 30.6 69 0
F30 19 29.1 313.2 1 N 0 0 33.1 19.2 0 N 0 0 N 0 0 N 0 0
B F31 21 33.1 3.3* 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
F32 19 33.1 2.6* 0 N 0* 0 32.6 6.2* 0 N 0 0 N 0 0 N 0* 0
F33 21 N 0* 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
F34 20 29.4 38* 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
F35 19 N 0* 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
C F49 20 32.3 26.5 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
F50 20 31.4 36.3 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
F52 19 N 0 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
F53 19 N 0 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
F54 21 30.4 23.3 0 N 0* 0 N 0* 0 N 0 0 N 0 0 N 0* 0
D F56 19 30.5 35.3 0 N 0 0 N 0* 0 N 0 0 N 0 0 N 0 0
F57 21 26.7 192.7 0 N 0 0 32.3 6.6* 0 N 0 0 N 0 0 N 0 0
F58 21 31.6 14 0 N 0 0 N 0* 0 N 0 0 N 0 0 N 0 0
F59 18 19.9 40297.1 62.2 30.6 44.7 0 34.3 1.9 0 33.7 1.9 0 33.8 4.3 0 31.8 14 0
F60 20 30.4 39.6 0 36.4 2.6 0 35.5 1.4* 0 N 0 0 N 0 0 N 0 0
E F13 19 28.3 111.6 0.6 30.8 17.9 0 32.7 3.9 0 39.7 0.1 0 36.3 0.3 0 N 0 0
F24 20 31.6 32.1 0 N 0 0 36.1 821.8 0 N 0 0 N 0 0 39.3 4.7 0
F27 14 21.3 132202.1 8.7 31.8 42 0 28.9 403.3 0 33.1 36.9 0 34.2 16.7 0 24.4 7793.8 37.9
F36 20 31 23.6 0 N 0 0 34.9 2 0 N 0 0 N 0 0 N 0 0
F42 5 27.3 514.8 47 20.7 318323 174.6 23.2 14400 76.2 25 5456.3 600.8 23.2 32118.9 94.4 24.8 6562.9 19
F43 20 30.9 38.2 0.4 33.7 11.4 0 36.5 1.5 0 N 0 0 41.4 0.1 0 41.5 0.1 0
F51 8 22.7 2667.5 737.9 22.5 8631 10.6 18.9 82090.5 2895.9 19.8 63844.1 7558.4 16.7 402895.4 3023.2 17.7 295310.6 4379.9
F55 3 31 12.3 0 23.9 2375.9 3.4 25.7 795.6 3.9 26.4 464.9 13.2 26.7 248.5 0.9 27.7 379.8 5.4
Abbreviations: Grp (group), ID (identification number), Dpi (days post infection), Ct (Ct values), Copies (copies per mg organ), TCID (tissue culture infectious dose 50 per mg organ), N (no Ct value). Viral genome copies
of brain, spleen, kidney and heart of all surviving birds of the vaccination groups were compared to the respective values of group E with one-sided Wilcoxon rank sum test with continuity correction and those with
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animals (p value 0.04762), but not in the spleen, heart and
brain of group D birds (p values 0.1726, 0.1187, 0.7262). No
significant reduction of viral genome detection in organs
was present in group A (p values of brain, spleen, kidney,
and heart: 0.5476, 0.6532, 0.5476, and 0.5, respectively).
Discussion
WNV infections can lead to subclinical or severe dis-
eases and mortality in falcons [27,30,35,37,51]. Free-ran-
ging birds play a major role in the spread of WNV over
large distances [15-17]. In order to protect raptors, vac-
cines destined for use in horses have recently been
tested in falcons [51]. As these show only sub-optimal effi-
cacy, more vaccine candidates were tested in the present
study. For this purpose, WNV DNA vaccines were chosen
because they had been used in raptors and other avian spe-
cies with promising results [34,40,45,46]. However, differ-
ences in their efficacy were observed for several avian
species [46]. Therefore, a species-specific efficacy study was
initiated to determine the rates of clinical protection and
the reduction of virus shedding, viral load and virus distri-
bution in large falcons.
In contrast to the WNV DNA vaccine used in previous
studies in raptors, which coded for prM and E glycopro-
teins of WNV [40], in the present study, two DNA vac-
cines encoding a secreted version of the E protein
ectodomain of WNV lineage 1 [52] (WNV-DNA-1) and 2
(WNV-DNA-2), respectively, were used. Previously, DNA
vaccines have been administered intramuscularly into the
leg muscles of raptors [34,46]. This administration corre-
sponds to findings in dogs, robins, and crows, where influ-
ences of the administration routes on humoral responses
were demonstrated. Intramuscular administration induced
stronger antibody responses compared to oral or intrader-
mal applications, respectively [40,41,45,57]. However, the
pectoral muscle is generally the preferred site for intramus-
cular drug administration in birds, due to the larger muscle
mass and possible rapid drug elimination by a renal portal
venous system from the leg muscles. Therefore, the pec-
toral muscles were preferred for intramuscular injection in
the falcons of groups A and B. Moreover, WNV-DNA-1
was administered using EP in two groups (groups C and D)
and boosted in the same way (group C) or with recombin-
ant WNV protein subcutaneously (group D) according to
successful studies in mice [52]. As EP has only been
sparsely reported in avian species [58] and impairment of
heart function by the electric impulses in the adjacent thor-
acic muscles could not be ruled out, vaccination and EP
were applied to the lower leg muscles in these groups.
Overall, the safety and acceptance of both vaccines and
the EP were good. There was no alteration in behavior,
food uptake, movement or general health condition in any
bird. In comparison to previous studies in falcons using arecombinant canarypox vectored WNV vaccine [51] no
remarkable loss of body weight was observed in this study,
but there was also local inflammation at the vaccination
sites. Two birds in group B developed an edematous/gelat-
inous texture of pectoral muscle which disappeared after
two weeks and could not be confirmed at necropsy. More-
over, mild, non-suppurative myositis and follicular aggre-
gates were seen at the vaccination sites of single birds in
groups B, C and D. Two falcons of group D developed a
moderate to severe granulomatous dermatitis. Taken to-
gether, most alterations were confined to groups which
were vaccinated twice and electroporated. Therefore, a re-
action to the extended vaccination scheme was suspected,
possibly caused by hypersensitivity reactions to the vaccine,
the adjuvant or the recombinant protein.
A possible shedding of the WNV vaccine plasmid by
immunized birds was investigated by taking cloacal and
pharyngeal swabs from all falcons on a weekly basis
(data not displayed). The fact that WNV DNA plasmid
was not found in any of these swabs highlights the envir-
onmental safety of these DNA plasmid vaccines used.
Elicited antibody titers were low in all four vaccination
groups and lasted for a maximum of 3 weeks in single
individuals. Moreover, many vaccinated birds failed to
produce detectable antibody levels, or titers were detect-
able on single days only but not repeatedly over weeks.
These results contrast strongly with DNA vaccination
reports in California and Andean condors, where all birds
demonstrated increased neutralizing antibody levels in
plaque-reduction test 4 wpv [34]. It also lags behind other
DNA vaccination studies, where in 15/19 American crows
and in 6/9 fish crows, neutralizing antibodies were dem-
onstrated [40,41]. Moreover, antibody levels were low com-
pared to previous studies in large falcons, using formalin-
inactivated WNV vaccines and recombinant canarypox live
WNV vaccines [51]. However, similar differences have been
shown in four penguin species, where higher antibody
levels were induced by an inactivated vaccine compared to
a DNA vaccine [39]. Low antibody titers had also been re-
ported in red tailed hawks, where only 3/14 birds developed
low titers (maximum titers 1:10) 4 wpv following DNA
vaccination [46]. Moreover, in 3/3 American robins, no
detectable antibody levels have been measured 2 wpv [45].
Thereby, species-specific differences may play a role in
humoral response, as previously discussed [46].
To solve the problem of low immunogenicity of DNA
vaccines, strategies such as in-vivo EP have been devel-
oped which result in a significant increase in humoral
and cellular immune responses [59]. However, antibody
responses were not markedly stronger using this ap-
proach in the present study. A likely explanation is that
DNA vaccination in falcons mainly enhances cellular
and/or innate immune mechanisms, as suggested for
other species [39,41,52,58,60,61] This might explain the
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the lower viral organ load in groups C and D compared
to group A.
Besides EP, antibody levels were recently further stimu-
lated using recombinant protein DIII in mice [52]. How-
ever, this failed in falcons of group D compared to falcons
of groups A and C in this study. This might be explained
by a possible lower efficacy of the adjuvant ISA 70 in
falcons compared to oligonucleotides (ODN 1826), which
have been used in the mice [52]. The importance of the
adjuvant has been shown in geese, where ISA720 induced
significantly higher antibody titers compared to vaccin-
ation of the subunit protein antigen without this adjuvant
[43]. In contrast, in crows, the adjuvant did not signifi-
cantly affect the performance of the DNA vaccine [41].
Antibody responses to virus challenge were poor in the
deceased or euthanized birds but were good in the surviv-
ing control birds. In the vaccinated birds, titers raised
from 3 dpi onwards in group B, and even higher in EP
groups C and D. Therefore, the first antibodies in vacci-
nated falcons were demonstrated three days earlier com-
pared to the first antibody detection in 4/8 control birds
and unvaccinated large falcons from a previous WNV
infection trial [37]. In a study in geese, a humoral response
by vaccinated birds was demonstrated by antibodies from
day six onwards following live virus challenge [43]. Similar
high seroconversion rates following DNA vaccination and
challenge have been reported in red-tailed hawks [46] and
crows [41]; however, in the hawks, seroconversion oc-
curred in 11/14 vaccinated birds only after challenge,
underlining the importance of live virus challenge in vac-
cine evaluation and assessment of clinical protection.
Passage of the challenge virus on Vero E6 cells may have
attenuated the virus. However, virus attenuation is very
unlikely, as the virus in the present study was taken as an
aliquot from the same virus stock and was therefore iden-
tical to the WNV which had been used successfully in two
previous infectious trials [37,51]. Moreover, similar to the
non-vaccinated falcons in previous studies [37,51], the
control animals in the present trial demonstrated clinical
signs, viremia, virus shedding, organic virus accumulation,
and pathological alterations associated to WNV infection.
There are indications that the occurrence of natural
WNV infections in captive and free-ranging peregrine
falcons is lower than that in gyrfalcons and gyr-hybrid-fal-
cons, despite the opportunity for exposure. Therefore, the
use of different falcon species and their hybrids might
have limited the evaluation of results. However, there is
no valid proof available that susceptibility to WNV varies
between falcon species, as this had been stated for other
viruses [62]. Moreover, the phylogenetic relationship be-
tween most of the falcon species used is so close [63-65]
that differences in the immunological reaction to vaccines
and virus challenge are unlikely. Accordingly, the results ofthe present study do not point towards any species suscep-
tibility; however, certain host variability should be taken
into account when interpreting results as it is known from
other studies using non-standard laboratory animals [66].
In groups B, C, and D, clinical scores were significantly
reduced and survival rates increased compared to the con-
trol group, while the survival rate of group A was low
(60%). One of the two deceased falcons in group A died,
most likely due to hemorrhagic enteritis, but demon-
strated no signs typical for a WNV-associated disease in
pathology, histopathology and IHC. It is possible that the
incubation time of about 4 dpi was too short to develop
clear signs of disease. A second falcon in group A and one
falcon in group D had to be euthanized before the end of
the trial. Interestingly, both animals demonstrated distinct
amounts of antigen in the brain and/or heart by IHC, even
without pathological alterations. All other vaccinated fal-
cons (17/20) survived the challenge trial without or with
mild clinical signs (n = 9), showing moderate to severe
signs (clinical score ≥2) temporarily on single days (n = 4)
or on 4-12 days (n = 4), respectively. However, in this
study, the rate of survivors in groups A and D, but not in
groups B and C, is lower compared to robins, where 3/3
vaccinated birds survived a challenge with WNV isolate
WN02 for two weeks [45]. Similarly, 9/9 fish crows [40],
14/14 vaccinated red-tail hawks [46], and 44/44 geese [43]
were protected from lethal WNV infection; however, in all
of these studies, all control and mock birds also survived
to the end of the infectious trial. Therefore, evaluation of
the true benefits of vaccination in these studies is limited.
In addition, the study of viral dissemination or pathological
examinations were far less complete in those studies. This
was not the case in the present study, where only 50% of
the non-vaccinated control falcons survived virus challenge,
suffering temporarily from moderate to severe clinical signs.
Whether species-specific differences, higher virus infection
doses in the present study or a different pathogenicity of
the WNV challenge strains used is responsible for this
remains unclear, but it highlights the fact that previous
studies in other avian species are not directly comparable
to the present study.
Independently of the vaccination scheme, almost all
animals revealed clear histopathological signs of a mild
to severe, non-suppurative (meningo-)encephalitis,
which was even accompanied by a mild to moderate,
non-suppurative myocarditis and/or arteritis in several
falcons. Thereby, vaccination WNV-DNA-1 and WNV-
DNA-2 did not prevent the development of patho-
logical lesions; however, individual variability among
the birds was high. Besides lesions which are typically
associated with WNV infections, several vaccinated and
non-vaccinated falcons revealed lymphohistiocytic infil-
trations in different tissues. Interestingly, only in three
of the surviving birds the WNV antigen was detected in
Fischer et al. Veterinary Research  (2015) 46:87 Page 17 of 19brain, myocardium or spleen, suggesting an early clear-
ance of viral antigen during the progress of disease, as
discussed before [51].
In accordance with previous studies in falcons, viremia
levels and virus shedding were high in non-vaccinated
control falcons, especially if birds died or had to be eutha-
nized during the trial [37]. In comparison, the levels but
not the duration of oral and cloacal (except group C) virus
shedding and viremia were significantly reduced in all vac-
cination groups. However, in the three surviving control
birds, viral genome detection was also negative for single
days or after 8-14 dpi, respectively. In most falcons, virus
shedding extended beyond the viremic period, which has
also been reported from other raptor species [46,67]. The
reduction of viremia levels is in accordance with other
studies. In DNA-vaccinated geese, the virus was absent
from the blood; however, oral shedding occurred on 3-6
dpi, suggesting virus replication and the absence of sterile
immunity [43]. In absence of mortality in the cited study,
viremia during challenge has been used as a surrogate for
mortality as known from different animal models for flavi-
viral diseases [43,68]. In robins [45] and fish-crows [40],
the viremia level was decreased below the infectious level
of mosquitoes, which has been reported to be 105 PFU/
mL blood [69]. However, this failed in crows, where
viremia levels were decreased from 1010 only to 105
PFU/mL blood [41]. In accordance to previous reports,
the results of this study suggest a reduction of the trans-
mission risk through blood sucking mosquitoes from
vaccinated birds.
High viral organ loads have been reported in falcons
infected with WNV lineages 1 and 2 previously [37], and
correspond to findings in the deceased birds of the present
study. Compared to the control group, viral load was sig-
nificantly reduced in most or all organs in groups B and C
and in single organs in group D, but not in group A. Simi-
lar to 2/4 surviving control birds in group E, virus genome
detection was successful from the brain of all birds in
group A. Moreover, in birds of group A, the viral genome
was detected in kidney, heart, spleen, liver and lung of
some falcons, especially in deceased animals. In contrast,
the number of falcons with positive virus detection in the
brain was reduced in groups B (n = 3) and C (n = 3), but
not in group D (n = 5), and positive virus detection from
other organs occurred only in one bird of group B and two
birds of group D, but not in group C. This reduction of
viral organ load corresponds to previous studies in falcons,
where inactivated and recombinant vaccines decreased the
viral organ load significantly [51].
In conclusion, the WNV DNA vaccines used in this
study induced partial protection against WNV associated
diseases and, depending on the route of administration,
full protection from death. Interestingly, WNV-DNA-2
provided cross-protection against the WNV lineage 1strain NY99. A similar cross-protection between different
WNV lineages has been reported in horses and mouse
studies [70]. Even if sterile immunity was not achieved, in
many cases virus shedding, viremia and viral loads in or-
gans were significantly decreased, reducing the risk of dis-
ease transmission from vaccinated birds. Although almost
all animals developed signs of disease, the survival rate
was higher compared to controls. From the practical point
of view, the results of WNV-DNA-2, which was injected
IM, are promising regarding the attenuation of virus shed-
ding and viremia. Also, EP of DNA led to 100% survival of
falcons; however, the set-up and availability of machines
for in-vivo EP generally currently limit the extensive use of
this technology for DNA-vaccines [59].
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